Skip to main content
. 2023 Apr 4;18(4):e0273202. doi: 10.1371/journal.pone.0273202

Fig 1. Time to progression towards ARDS and length of hospital stay of patients with baseline SuPAR ≥ 6 ng/mL who received and did not receive anakinra.

Fig 1

Time to progression to ARDS (A) and length of hospital stay (B) of patients admitted for COVID-19 with baseline SuPAR ≥ 6 ng/mL and non-severe respiratory failure who received and did not receive anakinra. ARDS was defined as PaO2/FiO2 < 150 mmHg and use of high-flow oxygen therapy/NIV or MV. COVID-19 = coronavirus disease 2019. ARDS = acute respiratory distress syndrome. SuPAR = soluble urokinase plasminogen activator receptor. HR = hazard ratio.